P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.633
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-46 Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-Small Cell Lung Cancer With the EGFR T790M Mutation, Detected From Circulating Tumor DNA: LiquidLung-O-Cohort 2

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

P1.01-111 EGFR Exon20 Insertion Patients Treated With First-Line Chemotherapy in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA16.06 EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy